Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016

  • ID: 3734758
  • Company Profile
  • 80 pages
  • Global Markets Direct
1 of 4
Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016

Summary

‘Ionis Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Ionis Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Ionis Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Ionis Pharmaceuticals, Inc.
- The report provides overview of Ionis Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Ionis Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Ionis Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Ionis Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ionis Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ionis Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Ionis Pharmaceuticals, Inc. Snapshot

Ionis Pharmaceuticals, Inc. Overview

Key Information

Key Facts

Ionis Pharmaceuticals, Inc. - Research and Development Overview

Key Therapeutic Areas

Ionis Pharmaceuticals, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Ionis Pharmaceuticals, Inc. - Pipeline Products Glance

Ionis Pharmaceuticals, Inc. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Ionis Pharmaceuticals, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Ionis Pharmaceuticals, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Ionis Pharmaceuticals, Inc. - Drug Profiles

nusinersen

Product Description

Mechanism of Action

R&D Progress

IONIS-463588

Product Description

Mechanism of Action

R&D Progress

IONIS-FXIRx

Product Description

Mechanism of Action

R&D Progress

IONIS-GCCRRx

Product Description

Mechanism of Action

R&D Progress

IONIS-GCGRRx

Product Description

Mechanism of Action

R&D Progress

IONIS-PTP1BRx

Product Description

Mechanism of Action

R&D Progress

ISIS-CRPRx

Product Description

Mechanism of Action

R&D Progress

IONIS-APOALRx

Product Description

Mechanism of Action

R&D Progress

IONIS-HTTRx

Product Description

Mechanism of Action

R&D Progress

IONISDMPK-2.5Rx

Product Description

Mechanism of Action

R&D Progress

ISIS-EIF4ERx

Product Description

Mechanism of Action

R&D Progress

ISIS-SOD1Rx

Product Description

Mechanism of Action

R&D Progress

IONIS-DGAT2Rx

Product Description

Mechanism of Action

R&D Progress

IONIS-HBV-LRx

Product Description

Mechanism of Action

R&D Progress

IONIS-HBVRx

Product Description

Mechanism of Action

R&D Progress

IONIS-PKKRx

Product Description

Mechanism of Action

R&D Progress

IONISGSK-4LRx

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotide to Inhibit C9ORF72 Protein for Amyotrophic Lateral Sclerosis

Product Description

Mechanism of Action

R&D Progress

IONIS-AGTLRx

Product Description

Mechanism of Action

R&D Progress

IONIS-TMPRSS6LRx

Product Description

Mechanism of Action

R&D Progress

IONISBIIB-4Rx

Product Description

Mechanism of Action

R&D Progress

IONISBIIB-5Rx

Product Description

Mechanism of Action

R&D Progress

IONISBIIB-6Rx

Product Description

Mechanism of Action

R&D Progress

ISIS-AATRx

Product Description

Mechanism of Action

R&D Progress

ISIS-FVIIRx

Product Description

Mechanism of Action

R&D Progress

ISIS-GHRLRx

Product Description

Mechanism of Action

R&D Progress

ISIS-RHO2.5Rx

Product Description

Mechanism of Action

R&D Progress

Antisense Oligonucleotides to Inhibit BCL11A and KLF1 for Hematological Disorders

Product Description

Mechanism of Action

R&D Progress

Ionis Pharmaceuticals, Inc. - Pipeline Analysis

Ionis Pharmaceuticals, Inc. - Pipeline Products by Target

Ionis Pharmaceuticals, Inc. - Pipeline Products by Route of Administration

Ionis Pharmaceuticals, Inc. - Pipeline Products by Molecule Type

Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action

Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates

Ionis Pharmaceuticals, Inc. - Dormant Projects

Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

ISIS-104838

ISIS-113715

ISIS-14803

ISIS-2503

ISIS-5132

ISIS-CRPRx

ISIS-EIF4ERx

Ionis Pharmaceuticals, Inc. - Company Statement

Ionis Pharmaceuticals, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Ionis Pharmaceuticals, Inc., Key Information

Ionis Pharmaceuticals, Inc., Key Facts

Ionis Pharmaceuticals, Inc. - Pipeline by Indication, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Ionis Pharmaceuticals, Inc. - Phase III, 2016

Ionis Pharmaceuticals, Inc. - Phase II, 2016

Ionis Pharmaceuticals, Inc. - Phase I, 2016

Ionis Pharmaceuticals, Inc. - Preclinical, 2016

Ionis Pharmaceuticals, Inc. - Discovery, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Target, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Ionis Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016

Ionis Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016

Ionis Pharmaceuticals, Inc. - Dormant Developmental Projects,2016

Ionis Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

Ionis Pharmaceuticals, Inc., Subsidiaries

List of Figures

Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016

Ionis Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016

Ionis Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016

Ionis Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll